ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumoursC. Coyle, Ruth E. Langley, Lindy Berkman et al.|Contemporary Clinical Trials|2016Cited by 162
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam‐Hogan, R. Steele, Fay Cafferty et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 64